Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53,536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current Strategies and Applications for Precision Drug Design.
Wang C, Xu P, Zhang L, Huang J, Zhu K, Luo C. Wang C, et al. Among authors: huang j. Front Pharmacol. 2018 Jul 18;9:787. doi: 10.3389/fphar.2018.00787. eCollection 2018. Front Pharmacol. 2018. PMID: 30072901 Free PMC article. Review.
Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion.
Sun Z, Zhang H, Zhang Y, Liao L, Zhou W, Zhang F, Lian F, Huang J, Xu P, Zhang R, Lu W, Zhu M, Tao H, Yang F, Ding H, Chen S, Yue L, Zhou B, Zhang N, Tan M, Jiang H, Chen K, Liu B, Liu C, Dang Y, Luo C. Sun Z, et al. Among authors: huang j. Adv Sci (Weinh). 2020 May 13;7(14):2000098. doi: 10.1002/advs.202000098. eCollection 2020 Jul. Adv Sci (Weinh). 2020. PMID: 32714746 Free PMC article.
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR, Li X, Liao LP, Han J, Huang J, Li JC, Tao HR, Fan SJ, Chen ZF, Li Q, Chen SJ, Ding H, Yang YX, Zhou B, Jiang HL, Chen KX, Zhang YY, Huang CX, Luo C. Zhou XR, et al. Among authors: huang j, huang cx. Acta Pharmacol Sin. 2022 Feb;43(2):457-469. doi: 10.1038/s41401-021-00643-2. Epub 2021 Apr 13. Acta Pharmacol Sin. 2022. PMID: 33850273 Free PMC article.
PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J, Wang C, Xu P, Li X, Lu Y, Jin D, Yin X, Jiang H, Huang J, Xiong H, Ye F, Jin J, Chen Y, Xie Y, Chen Z, Ding H, Zhang H, Liu R, Jiang H, Chen K, Yao Z, Luo C, Huang Y, Zhang Y, Zhang J. Wang J, et al. Among authors: huang j, huang y. Theranostics. 2021 Mar 12;11(11):5387-5403. doi: 10.7150/thno.42345. eCollection 2021. Theranostics. 2021. PMID: 33859753 Free PMC article.
53,536 results
You have reached the last available page of results. Please see the User Guide for more information.